Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 10, pp 463–469 | Cite as

Zinc l-carnosine in gastric ulcers: a profile of its use

  • Katherine A. Lyseng-WilliamsonEmail author
Adis Drug Q&A
  • 37 Downloads

Abstract

Oral zinc l-carnosine (Gastrozin®) 75 mg twice daily is an effective gastric mucoprotective option for the treatment and prevention of gastric ulcers. The two components of the chelated compound (i.e. zinc and l-carnosine in a 1:1 ratio) provide beneficial anti-inflammatory, antioxidant and other effects that work together to support the natural mucoprotective mechanisms of the gastrointestinal tract. Zinc l-carnosine 75 mg twice daily has well established efficacy in the treatment of gastric ulcers, and is at least as effective as other mucoprotectants in this indication. It consistently provides rapid healing of gastric ulcers regardless of their underlying cause, such as gastritis, Helicobacter pylori infection and endoscopic submucosal dissection (ESD), or concurrent pharmacological treatment (e.g. H. pylori eradication or proton pump inhibitor therapy).

Notes

Acknowledgements

The manuscript was reviewed by: H. Parthasarathy, Department of Cardiology, Apollo Hospitals, Chennai, India, Y. Prashar, Department of Pharmacology, Rayat Institute of Pharmacy, Railmajra, India; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India; A.K. Srivastava, Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, India. During the peer review process, Synergy Pharma, the marketing-authorization holder of the Gastrozin® formulation of zinc l-carnosine, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

KA. Lyseng-Williamson is an employee of Adis International Ltd./Springer Nature and the Editor of Drugs & Therapy Perspectives; she has no other conflicts of interest to declare. The Editor of D&TP was not involved in any publishing decisions for the manuscript.

References

  1. 1.
    Choi HS, Kim ES, Keum B, et al. l-carnosine and zinc in gastric protection. In: Preedy VR, editor. Food and Nutritional Components in Focus. Cambridge: Royal Society of Chemistry; 2015. p. 548–65.Google Scholar
  2. 2.
    Myran L, Zarbock SD. Management of Helicobacter pylori infection. US Pharm. 2019;43(4):27–32.Google Scholar
  3. 3.
    Gastrozin (75 mg zinc l-carnosine tablet): package leaflet. Dubai: Synergy Pharma. 2019.Google Scholar
  4. 4.
    Hudson T. Nutrient profile: zinc-carnosine: a combination of zinc and l-carnosine improves gastric ulcers. Natural Med J. 2013;5:11.Google Scholar
  5. 5.
    Matsukura T, Tanaka H. Applicability of zinc complex of l-carnosine for medical use. Biochem (Mosc). 2000;65(7):817–23.Google Scholar
  6. 6.
    Soderberg TA, Sunzel B, Holm S, et al. Antibacterial effect of zinc oxide in vitro. Scan J Plast Reconstr Sug Hand Surg. 1990;24(3):93–107.Google Scholar
  7. 7.
    Prasad A. Zinc: an overview. Nutrition. 1995;11(1 Suppl):93–9.PubMedGoogle Scholar
  8. 8.
    Opoka W, Adamek D, Plonka M, et al. Importance of luminal and mucosal zinc in the mechanism of experimental gastric ulcer healing. J Physiol Pharmacol. 2010;61(5):581–91.PubMedGoogle Scholar
  9. 9.
    Korolkiewicz R, Fujita A, Seto K, et al. Polaprezinc exerts a salutary effect on impaired healing of acute gastric lesions in diabetic rats. Dig Dis Sci. 2000;45(6):1200–9.CrossRefGoogle Scholar
  10. 10.
    Furata S, Toyama S, Miwa M, et al. Residence time of polaprezinc (zinc l-carnosine complex in the rat stomach and adhesiveness to ulcerous sites. Jpn J Pharmacol. 1995;67(4):271–8.CrossRefGoogle Scholar
  11. 11.
    Gaby AR. Therapeutic agents part 2B: minerals. Nutritional medicine. 2nd ed. Concord (NH): Nutritional Medicine. 2017.Google Scholar
  12. 12.
    Ito M, Tanaka T, Suzuki Y. Effect of N-(3-aminopropionyl)-l-histidinato zinc (Z-103) on healing and hydrocortisone-induced relapse of acetic acid ulcers in rats with limited food intake-time. Jpn J Pharmacol. 1990;52(4):513–21.CrossRefGoogle Scholar
  13. 13.
    Baan M, Sherding RG, Johnson SE. Effects of zinc-l-carnosine and vitamin E on aspirin-induced gastroduodenal injury in dogs. J Vet Intern Med. 2011;25(1):39–46.CrossRefGoogle Scholar
  14. 14.
    Naito Y, Yoshikawa T, Yagi N, et al. Effects of polaprezinc on lipid peroxidation, neutrophil accumulation, and TNF-α expression in rats with aspirin-induced gastric mucosal injury. Dig Dis Sci. 2001;46(4):845–51.CrossRefGoogle Scholar
  15. 15.
    Choi HS, Lim J, Chun HJ, et al. The effect of polaprezinc on gastric mucosal protection in rats with ethanol-induced gastric mucosal damage: comparison study with rebamipide. Life Sci. 2013;9(2–3):69–77.CrossRefGoogle Scholar
  16. 16.
    Ko JK, Leung CC. Ginger extract and polaprezinc exert gastroprotective actions by anti-oxidant and growth factor modulating effects in rats. J Gastroenterol Hepatol. 2010;25(12):1861–8.CrossRefGoogle Scholar
  17. 17.
    Shimada T, Watanabe N, Ohtuka Y, et al. Polaprezinc down-regulates proinflammatory cytokine-induced nuclear factor-κB activiation and interleukin-8 expression in gastric epithelial cells. J Pharmacol Exp Ther. 1999;291(1):345–52.PubMedGoogle Scholar
  18. 18.
    Handa O, Yoshida N, Tanaka Y, et al. Inhibitory effect of polaprezinc on the inflammatory response to Helicobacter pylori. Can J Gastroenterol. 2002;16(11):785–9.CrossRefGoogle Scholar
  19. 19.
    Ishihara R, Iishi H, Sakai N, et al. Polaprezinc attenuates Helicobacter pylori-associated gastritis in Mongolian gerbils. Helicobacter. 2002;7(6):384–9.CrossRefGoogle Scholar
  20. 20.
    Ito M, Shii D, Segami T, et al. Preventive actions of N-(3-aminopropionyl)-l-histidinato zinc (Z-103) through increases in the activities of oxygen-derived free radical scavenging enzymes in the gastric mucosa on ethanol-induced gastric mucosal damage in rats. Jpn J Pharmacol. 1992;59(3):267–77.CrossRefGoogle Scholar
  21. 21.
    Yoshikawa T, Naito Y, Tanigawa T, et al. The antioxidant properties of a novel zinc-carnosine chelate compound, N-(3-aminopropionyl)-l-histidinato zinc. Biochim Biophys Acta. 1991;1115(5):15–22.CrossRefGoogle Scholar
  22. 22.
    Ueda K, Ueyama T, Oka M, et al. Polaprezinc (zinc l-carnosine) is a potent inducer of anti-oxidative stress enzyme, heme oxygenase (HO)-1: a new mechanism of gastric mucosal protection. J Pharmacol Sci. 2009;110(3):285–94.CrossRefGoogle Scholar
  23. 23.
    Omatsu T, Naito Y, Handa O, et al. Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury. J Gastroenterol. 2010;45(7):692–702.CrossRefGoogle Scholar
  24. 24.
    Fujii Y, Matsura T, Kai M, et al. Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells. Jpn J Pharmacol. 2000;84(1):63–70.CrossRefGoogle Scholar
  25. 25.
    Yoshikawa T, Yamaguchi T, Yoshida N, et al. Effect of Z-103 on TNB-induced colitis in rats. Digestion. 1997;58(5):464–8.CrossRefGoogle Scholar
  26. 26.
    Hiraishi H, Sasai T, Oinuma T, et al. Polaprezinc protects gastric mucosal cells from noxious agents through antioxidant properties in vitro. Aliment Pharmacol Ther. 1999;13(2):261–9.CrossRefGoogle Scholar
  27. 27.
    Yoshikawa T, Naito Y, Tanigawa T, et al. Effect of zinc-carnosine chelate compound (Z-103), a novel antioxidant, on acute gastric mucosal injury induced by ischemia-reperfusion in rats. Free Radic Res Commun. 1991;14(4):289–96.CrossRefGoogle Scholar
  28. 28.
    Watanabe S, Wang XE, Hirose M, et al. Insulin-like growth factor I plays a role in gastric wound healing: evidence using a zinc derivative, polaprezinc, and an in vitro rabbit wound repair model. Aliment Pharmacol Ther. 1998;12(11):1131–8.CrossRefGoogle Scholar
  29. 29.
    Odashima M, Otaka M, Jin M, et al. Induction of a 72-kDa heat-shock protein in cultured rat gastric mucosal cells and rat gastric mucosa by zinc l-carnosine. Dig Dis Sci. 2001;47(12):2799–804.CrossRefGoogle Scholar
  30. 30.
    Wada I, Otaka M, Jin M, et al. Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats: correlation of HSP72 expression with mucosal protection. Biochem Biophys Res Commun. 2006;349(2):611–8.CrossRefGoogle Scholar
  31. 31.
    Mahmood A, FitzGerald AJ, Marchbank T, et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut. 2007;56(2):168–75.CrossRefGoogle Scholar
  32. 32.
    Watari I, Oka S, Tanaka S, et al. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterol. 2013;13:108.CrossRefGoogle Scholar
  33. 33.
    Mitani T, Shirasaka D, Miyachi H. Can polaprezinc be attributed to reduce the risk of gastric carcinogenesis in Helicobacter pylori-positive young people? [abstract no. 136]. Am J Gastroenterol. 2007;102(Suppl 2):S167.CrossRefGoogle Scholar
  34. 34.
    Murakami K, Sato R, Okimoto T, et al. Influence of anti-ulcer drugs used in Japan on the result of 13C-urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol. 2003;38(10):937–41.CrossRefGoogle Scholar
  35. 35.
    Miyoshi A, Matsuo H, Miwa T, et al. Clinical evaluation of Z-103 in the treatment of gastric ulcers: a multicenter double-blind dose finding study [in Japanese]. Jpn Pharmacol Ther. 1992;20(1):181–97.Google Scholar
  36. 36.
    Miyoshi A, Namiki M, Iwasaki A, et al. Clinical evaluation of Z-103 in the treatment of gastritis: a multicenter double-blind dose finding study [in Japanese]. Jpn Pharmacol Ther. 1997;25(5):1403–42.Google Scholar
  37. 37.
    Miyoshi A, Matsuo H, Miwa T, et al. Clinical evaluation of Z-103 in the treatment of gastritis: an open-label dose finding study [in Japanese]. Jpn Pharmacol Ther. 1992;20(1):245–54.Google Scholar
  38. 38.
    Miyoshi A, Matsuo H, Miwa T, et al. Clinical evaluation of Z-103 (polaprezinc) on gastric ulcer: a multicenter double-blind comparative study with cetraxate hydrochloride [in Japanese]. Jpn Pharmacol Ther. 1992;20(1):199–223.Google Scholar
  39. 39.
    Nakajima M. Clinical evaluation of Z-103 on gastritis: a double-blind controlled study using sucralfate as a comparator. Pharmacol Ther. 1997;25(4):325–66.Google Scholar
  40. 40.
    Kashimura H, Suzuki K, Hassan M, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther. 1999;13(4):483–7.CrossRefGoogle Scholar
  41. 41.
    Tan B, Luo HQ, Xu H, et al. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: a prospective, multicenter, randomized clinical trial. PLoS One. 2017;12(4):e0175625.CrossRefGoogle Scholar
  42. 42.
    Sugimoto N, Yoshikawa T, Naito Y, et al. Triple therapy of lansoprazole + amoxicillin + metronidazole versus triple plus mucosal protective drug polaprezinc therapy for cure of Helicobacter pylori (HP) in gastric ulcer patients [abstract]. Gastroenterology. 1997;112:A300.Google Scholar
  43. 43.
    Baniya R, Upadhaya S, Chughtai K, et al. Is polaprezinc a missing link in Helicobacter pylori eradication therapy? A meta-analysis of randomized controlled trials of triple therapy with polaprezinc [abstract no. 1249]. Am J Gastroenterol. 2017;112(Suppl 1):S680-S1.Google Scholar
  44. 44.
    Isomoto H, Furusu H, Ohnita K, et al. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. World J Gastroenterol. 2005;11(11):1629–33.CrossRefGoogle Scholar
  45. 45.
    Inaba T, Ishikawa S, Toyokawa T, et al. Basal protrusion of ulcers induced by endoscopic submucosal dissection (ESD) during treatment with proton pump inhibitors, and the suppressive effects of polaprezinc. Hepatogastroenterology. 2010;57(99–100):678–84.PubMedGoogle Scholar
  46. 46.
    Jung DH, Park JC, Lee YC, et al. Comparison of the efficacy of polaprezinc plus proton pump inhibitor and rebamipide plus proton pump inhibitor treatment for ESD-induced gastric ulcers: a randomized prospective controlled study [abstract no. Mo1107]. Gastrointest Endosc. 2017;85(5 Suppl 1):AB431.CrossRefGoogle Scholar
  47. 47.
    Dajani A, Abuhammour A. A modified sequential regimen of Helicobacter pylori treatment enforced by Bacillus clausii and zinc carnosine complex yields high eradication rates [abstract no. P-0040]. J Gastroenterol Hepatol. 2017;32(Suppl 3):61–2.Google Scholar
  48. 48.
    Dajani AI, Nounou MA, Fayadh MH, et al. Zinc carnosine complex improves the response to triple therapy of Helicobacter pylori eradication [abstract no. P-0279]. J Gastroenterol Hepatol. 2017;32(Suppl 3):72.Google Scholar
  49. 49.
    Ardesia M, Fries W, Palombieri A, et al. Influence of polaprezinc on efficacy of Helicobacter pylori eradication therapy in Italian population [abstract no. P.02.14]. Dig Liver Dis. 2017;49(Suppl 2):e143.CrossRefGoogle Scholar
  50. 50.
    Ishihama H, Sayo S, Yokoyama T, et al. Preventive and therapeutic effects of polaprezinc suspension on oral mucosal injury [abstract no. P1-032]. Ann Oncol. 2013;24(Suppl 9):ix66.CrossRefGoogle Scholar
  51. 51.
    Watanabe T, Ishihara M, Matsuura K, et al. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. Int J Cancer. 2010;127(8):1984–90.CrossRefGoogle Scholar
  52. 52.
    Yanase K, Funaguchi N, Iihara H, et al. Prevention of radiation esophagitis by polaprezinc (zinc l-carnosine) in patients with non-small cell lung cancer who received chemoradiotherapy. Int J Clin Exp Med. 2015;8(9):16215–22.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Sakae K, Agata T, Kamide R, et al. Effects of l-carnosine and its zinc complex (polaprezinc) on pressure ulcer healing. Nutr Clin Pract. 2013;28(5):609–16.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations